| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Head and Neck Neoplasms | 44 | 2023 | 1073 | 3.830 |
Why?
|
| Carcinoma, Squamous Cell | 26 | 2018 | 1077 | 1.980 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 29 | 2021 | 2544 | 1.480 |
Why?
|
| Antineoplastic Agents | 16 | 2019 | 2303 | 1.200 |
Why?
|
| B7-H1 Antigen | 2 | 2023 | 305 | 1.180 |
Why?
|
| Thrombocytopenia | 1 | 2020 | 189 | 0.610 |
Why?
|
| Pharmaceutical Preparations | 1 | 2020 | 97 | 0.600 |
Why?
|
| Sarcoma | 5 | 2015 | 222 | 0.580 |
Why?
|
| ErbB Receptors | 4 | 2016 | 506 | 0.530 |
Why?
|
| Biomarkers, Tumor | 5 | 2023 | 1660 | 0.520 |
Why?
|
| Biopsy | 2 | 2019 | 1175 | 0.490 |
Why?
|
| Bone Neoplasms | 3 | 2013 | 313 | 0.400 |
Why?
|
| Taxoids | 5 | 2014 | 126 | 0.380 |
Why?
|
| Combined Modality Therapy | 18 | 2010 | 1723 | 0.370 |
Why?
|
| Epidermal Growth Factor | 2 | 2012 | 115 | 0.370 |
Why?
|
| Paclitaxel | 11 | 2008 | 479 | 0.360 |
Why?
|
| Fluorouracil | 14 | 2014 | 524 | 0.360 |
Why?
|
| Humans | 73 | 2023 | 93522 | 0.350 |
Why?
|
| Antibodies, Monoclonal, Humanized | 7 | 2021 | 1001 | 0.330 |
Why?
|
| Aged | 40 | 2021 | 20439 | 0.310 |
Why?
|
| Survival Rate | 13 | 2019 | 1948 | 0.300 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 3 | 2003 | 158 | 0.300 |
Why?
|
| Neoplasms | 7 | 2023 | 3169 | 0.300 |
Why?
|
| Radiotherapy | 1 | 2010 | 320 | 0.280 |
Why?
|
| Middle Aged | 39 | 2021 | 27580 | 0.260 |
Why?
|
| Male | 46 | 2021 | 44564 | 0.250 |
Why?
|
| Osteosarcoma | 2 | 2004 | 158 | 0.250 |
Why?
|
| Aged, 80 and over | 18 | 2021 | 7063 | 0.250 |
Why?
|
| Hydroxyurea | 12 | 2014 | 231 | 0.250 |
Why?
|
| Red-Cell Aplasia, Pure | 1 | 2006 | 5 | 0.250 |
Why?
|
| Paraneoplastic Syndromes | 1 | 2006 | 16 | 0.240 |
Why?
|
| Antibodies, Monoclonal | 5 | 2015 | 1395 | 0.240 |
Why?
|
| Carcinoma, Basal Cell | 1 | 2006 | 63 | 0.240 |
Why?
|
| Prognosis | 12 | 2019 | 3912 | 0.230 |
Why?
|
| Adult | 34 | 2021 | 27921 | 0.230 |
Why?
|
| Female | 45 | 2021 | 48708 | 0.220 |
Why?
|
| Advance Care Planning | 2 | 2016 | 44 | 0.220 |
Why?
|
| Deglutition Disorders | 3 | 2018 | 126 | 0.210 |
Why?
|
| Treatment Outcome | 16 | 2018 | 9103 | 0.210 |
Why?
|
| Soft Tissue Neoplasms | 1 | 2004 | 124 | 0.200 |
Why?
|
| Melanoma | 2 | 2021 | 495 | 0.200 |
Why?
|
| Skin Neoplasms | 2 | 2006 | 620 | 0.200 |
Why?
|
| Hemangiosarcoma | 3 | 2012 | 16 | 0.190 |
Why?
|
| Quality of Life | 8 | 2018 | 1780 | 0.190 |
Why?
|
| Quinazolines | 3 | 2010 | 211 | 0.190 |
Why?
|
| Neoplasm Recurrence, Local | 8 | 2015 | 1448 | 0.190 |
Why?
|
| Disease-Free Survival | 11 | 2013 | 1170 | 0.190 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2023 | 106 | 0.190 |
Why?
|
| Molecular Targeted Therapy | 2 | 2016 | 304 | 0.180 |
Why?
|
| Cetuximab | 3 | 2012 | 118 | 0.170 |
Why?
|
| Lymphatic Metastasis | 1 | 2023 | 504 | 0.170 |
Why?
|
| Breast Neoplasms | 4 | 2001 | 3110 | 0.170 |
Why?
|
| Ipilimumab | 1 | 2021 | 63 | 0.170 |
Why?
|
| Lactones | 1 | 2001 | 27 | 0.170 |
Why?
|
| Venous Thromboembolism | 1 | 2023 | 168 | 0.170 |
Why?
|
| Spouses | 1 | 2020 | 31 | 0.160 |
Why?
|
| Trastuzumab | 1 | 2020 | 86 | 0.160 |
Why?
|
| Thrombosis | 1 | 2023 | 309 | 0.160 |
Why?
|
| Radiation-Sensitizing Agents | 1 | 2000 | 97 | 0.150 |
Why?
|
| Antineoplastic Agents, Phytogenic | 2 | 2003 | 270 | 0.150 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 2 | 1996 | 939 | 0.150 |
Why?
|
| Alanine | 1 | 2019 | 83 | 0.150 |
Why?
|
| Triazines | 1 | 2019 | 54 | 0.150 |
Why?
|
| Antibodies | 1 | 2020 | 348 | 0.150 |
Why?
|
| Medical Oncology | 3 | 2016 | 404 | 0.140 |
Why?
|
| Neoplasms, Second Primary | 3 | 2013 | 245 | 0.140 |
Why?
|
| Withholding Treatment | 1 | 2019 | 121 | 0.140 |
Why?
|
| Pharyngeal Neoplasms | 1 | 2018 | 15 | 0.140 |
Why?
|
| Neoplasm Staging | 12 | 2015 | 2017 | 0.140 |
Why?
|
| Lymphoma | 1 | 2000 | 247 | 0.140 |
Why?
|
| Immunohistochemistry | 2 | 2019 | 1799 | 0.140 |
Why?
|
| Receptor, IGF Type 1 | 2 | 2015 | 45 | 0.140 |
Why?
|
| Heart Diseases | 1 | 2000 | 257 | 0.130 |
Why?
|
| Lung Diseases | 1 | 2000 | 283 | 0.130 |
Why?
|
| Communication | 1 | 2020 | 434 | 0.130 |
Why?
|
| Reproducibility of Results | 1 | 2023 | 2715 | 0.130 |
Why?
|
| Intubation, Intratracheal | 1 | 2018 | 159 | 0.130 |
Why?
|
| Neoplasm Metastasis | 4 | 2009 | 1061 | 0.120 |
Why?
|
| Drug Therapy | 1 | 2016 | 68 | 0.120 |
Why?
|
| Terminal Care | 2 | 2016 | 146 | 0.120 |
Why?
|
| Neoplasms, Germ Cell and Embryonal | 1 | 2016 | 57 | 0.120 |
Why?
|
| Drug Design | 1 | 2016 | 133 | 0.120 |
Why?
|
| Drug Administration Schedule | 7 | 2010 | 829 | 0.110 |
Why?
|
| Pharyngectomy | 1 | 2015 | 8 | 0.110 |
Why?
|
| Testicular Neoplasms | 1 | 2016 | 120 | 0.110 |
Why?
|
| Clinical Trials, Phase II as Topic | 3 | 2004 | 161 | 0.110 |
Why?
|
| Bone Marrow | 1 | 1996 | 409 | 0.110 |
Why?
|
| Patient Care Planning | 1 | 2015 | 87 | 0.110 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2016 | 188 | 0.110 |
Why?
|
| Camptothecin | 2 | 2009 | 196 | 0.110 |
Why?
|
| Self Care | 1 | 2015 | 167 | 0.100 |
Why?
|
| Outpatients | 1 | 2014 | 104 | 0.100 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2016 | 224 | 0.100 |
Why?
|
| Clinical Trials as Topic | 4 | 2016 | 1103 | 0.100 |
Why?
|
| Health Promotion | 1 | 2015 | 170 | 0.100 |
Why?
|
| Health Personnel | 1 | 2016 | 234 | 0.100 |
Why?
|
| Lung Neoplasms | 1 | 2006 | 2365 | 0.100 |
Why?
|
| Incidence | 5 | 2008 | 1702 | 0.100 |
Why?
|
| Oropharyngeal Neoplasms | 1 | 2015 | 149 | 0.100 |
Why?
|
| Patient-Centered Care | 1 | 2015 | 220 | 0.100 |
Why?
|
| Spinal Cord | 1 | 1994 | 241 | 0.100 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2011 | 920 | 0.100 |
Why?
|
| Follow-Up Studies | 5 | 2019 | 3832 | 0.100 |
Why?
|
| Hemangioendothelioma, Epithelioid | 1 | 2012 | 9 | 0.090 |
Why?
|
| Carboplatin | 4 | 2008 | 322 | 0.090 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2016 | 636 | 0.090 |
Why?
|
| Radiotherapy Dosage | 5 | 2006 | 472 | 0.090 |
Why?
|
| Proto-Oncogene Proteins B-raf | 1 | 2013 | 162 | 0.090 |
Why?
|
| Patient Education as Topic | 1 | 2015 | 373 | 0.090 |
Why?
|
| Sirolimus | 1 | 2013 | 176 | 0.090 |
Why?
|
| Indoles | 1 | 2013 | 303 | 0.090 |
Why?
|
| Models, Statistical | 1 | 2015 | 585 | 0.090 |
Why?
|
| Risk Factors | 5 | 2023 | 5901 | 0.090 |
Why?
|
| Sulfonamides | 1 | 2013 | 331 | 0.080 |
Why?
|
| Salvage Therapy | 4 | 2008 | 235 | 0.080 |
Why?
|
| Attitude of Health Personnel | 1 | 2016 | 660 | 0.080 |
Why?
|
| Methotrexate | 1 | 2011 | 225 | 0.080 |
Why?
|
| Immunotherapy | 1 | 2016 | 761 | 0.080 |
Why?
|
| Quality Improvement | 1 | 2014 | 485 | 0.080 |
Why?
|
| Surveys and Questionnaires | 4 | 2016 | 2802 | 0.080 |
Why?
|
| Mouth Neoplasms | 1 | 2012 | 202 | 0.080 |
Why?
|
| Developing Countries | 1 | 2010 | 91 | 0.080 |
Why?
|
| Polyethylene Glycols | 1 | 2012 | 373 | 0.080 |
Why?
|
| Remission Induction | 4 | 2008 | 738 | 0.080 |
Why?
|
| Leiomyoma | 1 | 2013 | 211 | 0.080 |
Why?
|
| Time Factors | 4 | 2015 | 5412 | 0.070 |
Why?
|
| Benzenesulfonates | 1 | 2009 | 49 | 0.070 |
Why?
|
| Blood Coagulation Factor Inhibitors | 1 | 2008 | 4 | 0.070 |
Why?
|
| United States | 5 | 2010 | 7622 | 0.070 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2013 | 603 | 0.070 |
Why?
|
| Administration, Oral | 4 | 2012 | 657 | 0.070 |
Why?
|
| Erlotinib Hydrochloride | 1 | 2008 | 86 | 0.070 |
Why?
|
| Blood Coagulation Disorders | 1 | 2008 | 66 | 0.070 |
Why?
|
| Interdisciplinary Communication | 2 | 2008 | 133 | 0.070 |
Why?
|
| Cisplatin | 3 | 2014 | 568 | 0.070 |
Why?
|
| Feasibility Studies | 3 | 2020 | 756 | 0.070 |
Why?
|
| Pyridines | 1 | 2009 | 303 | 0.060 |
Why?
|
| Transplantation, Autologous | 2 | 2000 | 359 | 0.060 |
Why?
|
| Doxorubicin | 2 | 2015 | 284 | 0.060 |
Why?
|
| Heart Failure | 1 | 2016 | 1386 | 0.060 |
Why?
|
| Signal Transduction | 1 | 2016 | 3502 | 0.060 |
Why?
|
| Prospective Studies | 2 | 2023 | 4562 | 0.060 |
Why?
|
| Survival Analysis | 5 | 2012 | 1524 | 0.060 |
Why?
|
| Pilot Projects | 2 | 2020 | 917 | 0.060 |
Why?
|
| Recombinant Proteins | 3 | 2003 | 988 | 0.060 |
Why?
|
| Neoplasm Invasiveness | 2 | 2004 | 572 | 0.050 |
Why?
|
| Dermatofibrosarcoma | 1 | 2004 | 13 | 0.050 |
Why?
|
| Young Adult | 5 | 2015 | 6930 | 0.050 |
Why?
|
| Radionuclide Imaging | 1 | 2004 | 189 | 0.050 |
Why?
|
| Rhabdomyosarcoma | 1 | 2004 | 43 | 0.050 |
Why?
|
| Chondrosarcoma | 1 | 2004 | 54 | 0.050 |
Why?
|
| Adolescent | 6 | 2018 | 9607 | 0.050 |
Why?
|
| Neck Dissection | 1 | 2004 | 67 | 0.050 |
Why?
|
| Radiation Tolerance | 1 | 2004 | 175 | 0.050 |
Why?
|
| Postoperative Complications | 1 | 2015 | 2563 | 0.050 |
Why?
|
| Factor V | 1 | 2023 | 9 | 0.050 |
Why?
|
| Prothrombin | 1 | 2023 | 19 | 0.050 |
Why?
|
| Cancer Care Facilities | 1 | 2003 | 36 | 0.050 |
Why?
|
| Travel | 1 | 2003 | 73 | 0.050 |
Why?
|
| Analysis of Variance | 2 | 2006 | 884 | 0.050 |
Why?
|
| Uracil | 2 | 1999 | 54 | 0.040 |
Why?
|
| Chemotherapy, Adjuvant | 4 | 2006 | 512 | 0.040 |
Why?
|
| Vascular Neoplasms | 1 | 2001 | 21 | 0.040 |
Why?
|
| Bryostatins | 1 | 2001 | 14 | 0.040 |
Why?
|
| Macrolides | 1 | 2001 | 30 | 0.040 |
Why?
|
| Neoplasms, Radiation-Induced | 1 | 2001 | 96 | 0.040 |
Why?
|
| Retrospective Studies | 5 | 2018 | 10166 | 0.040 |
Why?
|
| Antimetabolites, Antineoplastic | 2 | 1999 | 244 | 0.040 |
Why?
|
| Otorhinolaryngologic Neoplasms | 1 | 2000 | 4 | 0.040 |
Why?
|
| Hematopoietic Stem Cell Mobilization | 1 | 2000 | 52 | 0.040 |
Why?
|
| Patient Selection | 1 | 2003 | 690 | 0.040 |
Why?
|
| Breast | 1 | 2001 | 294 | 0.040 |
Why?
|
| Maximum Tolerated Dose | 2 | 2015 | 259 | 0.040 |
Why?
|
| Predictive Value of Tests | 2 | 2003 | 1713 | 0.040 |
Why?
|
| Cyclophosphamide | 1 | 2000 | 278 | 0.040 |
Why?
|
| Bone Marrow Transplantation | 1 | 2000 | 281 | 0.040 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2012 | 876 | 0.040 |
Why?
|
| Oxidoreductases | 1 | 1999 | 111 | 0.040 |
Why?
|
| Social Support | 1 | 2020 | 233 | 0.040 |
Why?
|
| Mutation | 2 | 2023 | 4272 | 0.040 |
Why?
|
| Disease Progression | 3 | 2012 | 1531 | 0.030 |
Why?
|
| Transplantation Conditioning | 1 | 2000 | 383 | 0.030 |
Why?
|
| Stroke Volume | 1 | 2000 | 440 | 0.030 |
Why?
|
| Pyrazines | 1 | 1998 | 93 | 0.030 |
Why?
|
| alpha-Fetoproteins | 1 | 2016 | 45 | 0.030 |
Why?
|
| Logistic Models | 1 | 2000 | 1243 | 0.030 |
Why?
|
| Cell Separation | 1 | 1996 | 200 | 0.030 |
Why?
|
| Vascular Endothelial Growth Factor A | 2 | 2009 | 398 | 0.030 |
Why?
|
| Smoking | 1 | 2000 | 648 | 0.030 |
Why?
|
| Age Factors | 1 | 2000 | 1906 | 0.030 |
Why?
|
| Transitional Care | 1 | 2015 | 20 | 0.030 |
Why?
|
| DNA Mutational Analysis | 1 | 2016 | 543 | 0.030 |
Why?
|
| Cardiology | 1 | 2016 | 120 | 0.030 |
Why?
|
| Physicians, Primary Care | 1 | 2016 | 109 | 0.030 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2016 | 283 | 0.030 |
Why?
|
| Radiotherapy, Adjuvant | 2 | 2006 | 314 | 0.030 |
Why?
|
| Survivors | 1 | 2015 | 204 | 0.030 |
Why?
|
| Veins | 1 | 1994 | 87 | 0.030 |
Why?
|
| Documentation | 1 | 2014 | 97 | 0.030 |
Why?
|
| Ambulatory Care | 1 | 2015 | 193 | 0.030 |
Why?
|
| Cost-Benefit Analysis | 1 | 2016 | 492 | 0.030 |
Why?
|
| Induction Chemotherapy | 1 | 2014 | 146 | 0.020 |
Why?
|
| Continuity of Patient Care | 1 | 2015 | 176 | 0.020 |
Why?
|
| Recurrence | 1 | 1996 | 1191 | 0.020 |
Why?
|
| Arteries | 1 | 1994 | 171 | 0.020 |
Why?
|
| Terminology as Topic | 1 | 1994 | 218 | 0.020 |
Why?
|
| Kidney Neoplasms | 1 | 1998 | 546 | 0.020 |
Why?
|
| 4-Nitroquinoline-1-oxide | 1 | 2012 | 15 | 0.020 |
Why?
|
| Amino Acid Substitution | 1 | 2013 | 331 | 0.020 |
Why?
|
| Administration, Topical | 1 | 2012 | 80 | 0.020 |
Why?
|
| Rats, Inbred F344 | 1 | 2012 | 160 | 0.020 |
Why?
|
| Cyclin D1 | 1 | 2012 | 85 | 0.020 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2012 | 76 | 0.020 |
Why?
|
| Mouth Mucosa | 1 | 2012 | 71 | 0.020 |
Why?
|
| Chemoprevention | 1 | 2012 | 93 | 0.020 |
Why?
|
| Liver Neoplasms | 1 | 1998 | 776 | 0.020 |
Why?
|
| Mutation, Missense | 1 | 2013 | 297 | 0.020 |
Why?
|
| Chemoradiotherapy | 1 | 2014 | 326 | 0.020 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2013 | 215 | 0.020 |
Why?
|
| Neoplasm Grading | 1 | 2013 | 402 | 0.020 |
Why?
|
| Bevacizumab | 1 | 2012 | 256 | 0.020 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2013 | 202 | 0.020 |
Why?
|
| Databases, Factual | 1 | 2015 | 1006 | 0.020 |
Why?
|
| Electronic Health Records | 1 | 2014 | 372 | 0.020 |
Why?
|
| Blotting, Western | 1 | 2012 | 784 | 0.020 |
Why?
|
| Down-Regulation | 1 | 2012 | 524 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 2016 | 1847 | 0.020 |
Why?
|
| Cell Cycle | 1 | 2012 | 515 | 0.020 |
Why?
|
| T-Lymphocytes | 1 | 2016 | 1275 | 0.020 |
Why?
|
| Lymph Nodes | 2 | 2004 | 548 | 0.020 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2012 | 457 | 0.020 |
Why?
|
| Colorectal Neoplasms | 1 | 1998 | 1053 | 0.020 |
Why?
|
| Cyclooxygenase 2 | 1 | 2009 | 99 | 0.020 |
Why?
|
| Cohort Studies | 2 | 2008 | 3056 | 0.020 |
Why?
|
| Niacinamide | 1 | 2009 | 101 | 0.020 |
Why?
|
| Blood Coagulation Tests | 1 | 2008 | 32 | 0.020 |
Why?
|
| Phenylurea Compounds | 1 | 2009 | 97 | 0.020 |
Why?
|
| Glucuronosyltransferase | 1 | 2009 | 184 | 0.020 |
Why?
|
| Epithelial Cells | 1 | 2012 | 700 | 0.020 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 2008 | 193 | 0.020 |
Why?
|
| Population Surveillance | 1 | 2008 | 213 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2016 | 2585 | 0.020 |
Why?
|
| Animals | 2 | 2012 | 28155 | 0.020 |
Why?
|
| Cell Proliferation | 1 | 2012 | 1741 | 0.010 |
Why?
|
| Cell Line, Tumor | 1 | 2012 | 2755 | 0.010 |
Why?
|
| Rats | 1 | 2012 | 4072 | 0.010 |
Why?
|
| Transforming Growth Factor alpha | 1 | 2005 | 49 | 0.010 |
Why?
|
| Deglutition | 1 | 2006 | 85 | 0.010 |
Why?
|
| Multicenter Studies as Topic | 1 | 2004 | 181 | 0.010 |
Why?
|
| Biopsy, Needle | 1 | 2004 | 225 | 0.010 |
Why?
|
| Probability | 1 | 2004 | 355 | 0.010 |
Why?
|
| Hospitals, University | 1 | 2003 | 188 | 0.010 |
Why?
|
| Filgrastim | 1 | 2003 | 56 | 0.010 |
Why?
|
| Bias | 1 | 2003 | 137 | 0.010 |
Why?
|
| Cause of Death | 1 | 2004 | 273 | 0.010 |
Why?
|
| Erythropoietin | 1 | 2003 | 90 | 0.010 |
Why?
|
| Neutropenia | 1 | 2003 | 209 | 0.010 |
Why?
|
| Odds Ratio | 1 | 2003 | 712 | 0.010 |
Why?
|
| Case-Control Studies | 1 | 2006 | 1932 | 0.010 |
Why?
|
| Proportional Hazards Models | 1 | 2003 | 889 | 0.010 |
Why?
|
| Multivariate Analysis | 1 | 2003 | 988 | 0.010 |
Why?
|
| Mastectomy, Segmental | 1 | 2001 | 107 | 0.010 |
Why?
|
| Infusions, Intravenous | 1 | 2001 | 401 | 0.010 |
Why?
|
| Referral and Consultation | 1 | 2003 | 375 | 0.010 |
Why?
|
| Comorbidity | 1 | 2004 | 1007 | 0.010 |
Why?
|
| Barium Sulfate | 1 | 2000 | 39 | 0.010 |
Why?
|
| Lymphedema | 1 | 2001 | 84 | 0.010 |
Why?
|
| Fluoroscopy | 1 | 2000 | 129 | 0.010 |
Why?
|
| Illinois | 1 | 2001 | 520 | 0.010 |
Why?
|
| Dihydrouracil Dehydrogenase (NADP) | 1 | 1999 | 28 | 0.010 |
Why?
|
| Chicago | 1 | 2003 | 1464 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2003 | 1914 | 0.010 |
Why?
|
| Tegafur | 1 | 1998 | 17 | 0.010 |
Why?
|
| Video Recording | 1 | 2000 | 212 | 0.010 |
Why?
|
| Etoposide | 1 | 1998 | 204 | 0.010 |
Why?
|
| Skin | 1 | 2001 | 578 | 0.010 |
Why?
|
| Cell Count | 1 | 1998 | 197 | 0.010 |
Why?
|
| Radiography | 1 | 1999 | 790 | 0.010 |
Why?
|
| Enzyme Inhibitors | 1 | 1999 | 641 | 0.010 |
Why?
|
| Contrast Media | 1 | 2000 | 988 | 0.010 |
Why?
|